查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609964

美國自動化細胞處理/封閉式細胞治療處理系統市場規模、佔有率和趨勢分析報告：按工作流程、類型、規模和細分市場進行預測，2025-2030 年

U.S. Automated And Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report By Workflow (Separation, Expansion), By Type (Stem Cell Therapy, Non-stem Cell Therapy), By Scale, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 75 Pages | 商品交期: 2-10個工作天內

價格

美國自動化細胞處理和封閉式細胞治療處理系統市場的成長和趨勢

Grand View Research, Inc.最新報告顯示，到2030年，美國自動化細胞處理和封閉式細胞治療處理系統市場規模將達到18.7億美元，2025年至2030年複合年成長率為19.41%。 。

對再生醫學和細胞療法的日益關注、自動化系統相對於手動處理的操作優勢以及廣泛不斷的技術進步是推動市場成長的一些關鍵因素。

人們對再生醫學的認知不斷提高，預計將推動對細胞治療的需求，並最終推動對自動化和封閉式細胞治療處理系統的需求，從而推動市場成長。例如，2024年9月，Arsenal Biosciences完成了3.25億美元的C輪資金籌措並獲得超額認購。借助這筆資金籌措，該公司將推進針對固體癌的CAR T 細胞療法。現有投資者支持該公司，包括帕剋癌症免疫治療研究所、Softbank CorporationVision Fund 2、百時美施貴寶、Westlake Village BioPartners、Kleiner Perkins、Byers Capital 和 Hitachi Ventures。

我強調，COVID-19 大流行凸顯了細胞療法對可擴展和彈性製造的迫切需求，以及隨著治療需求的增加，自動化系統在確保一致和可重複的品質流程方面的作用。自動化可以幫助面臨勞動力限制的公司維持生產標準，這使其對於當前和未來的治療需求至關重要。自動化系統的日益普及凸顯了該技術在建立可靠、高品質的細胞治療製造方面的作用。

儘管取得了這些進展，疫情也對美國自動化細胞處理和封閉式細胞治療處理系統市場產生了負面影響。全球供應鏈中斷導致生產和分銷延遲，限制了維持基本設備和材料穩定供應線的能力。此外，資源用於 COVID-19 治療，暫停了某些細胞治療計劃並減緩了創新。因此，細胞治療藥物的一些開發和生產計劃被延長，在短期內影響了研究和商業化。

此外，大量正在進行的臨床試驗以及政府機構為加速細胞療法研究和開發而不斷增加的支持是美國市場的主要促進因素。例如，2024 年 10 月，紐約州在長島推出了雄心勃勃、耗資 4.3 億美元的生物起源公園計劃。憑藉 1.5 億美元的國家投資以及與當地組織的合作，該設施旨在成為細胞和基因治療創新的領先中心。這些努力預計將加速細胞療法製造自動化系統的採用。

然而，這項技術相對較新，需要對過程有深入的了解和明確的策略才能達到預期的結果。此外，有必要為系統提供足夠的資料來理解該過程。完成此步驟後，您需要了解自動化的流程控制。整個過程需要熟練的人力和高階設備。缺乏可以實現細胞治療過程自動化的兼容硬體平台。由於大量的資本需求，預計市場成長將受到一定程度的阻礙。

美國自動化細胞處理/閉式細胞治療處理系統市場報告亮點

  • 根據工作流程，預計分離細分市場將在 2024 年以 31.10% 的最高收益佔有率主導市場，並在預測期內以最快的複合年成長率成長。這一巨大佔有率是由於治療應用對有效細胞分離和精製技術的需求不斷增加。
  • 從類型來看，非幹細胞治療領域佔據市場主導地位，2024年市佔率為61.84%。這是由於非幹細胞治療應用的產品推出增加。
  • 從規模來看，預商用/研發規模細分市場佔比最大，2024年達74.96%。這些系統主要用於早期研究、製程開發和臨床試驗。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國自動化細胞處理/閉孔細胞治療處理系統市場：依工作流程進行業務分析

  • 工作流程細分儀表板
  • 美國自動化細胞處理/封閉式細胞治療處理系統市場工作流程波動分析
  • 2018-2030年美國自動化細胞處理/封閉式細胞治療處理系統市場規模與趨勢分析（依工作流程）
  • 分離
  • 擴張
  • 血漿分離術
  • 填充完成
  • 冷凍保存
  • 其他

第5章美國自動化細胞處理/閉式細胞治療處理系統市場：按類型分類的業務分析

  • 類型細分儀表板
  • 美國自動化細胞處理/封閉式細胞治療處理系統市場類型及波動分析
  • 2018-2030年美國自動化細胞處理/封閉式細胞治療處理系統市場規模及類型趨勢分析
  • 幹細胞療法
  • 非幹細胞療法

第6章美國自動化細胞處理/閉式細胞治療處理系統市場：按規模進行的業務分析

  • 刻度細分儀表板
  • 美國自動化細胞處理/封閉式細胞治療處理系統市場規模波動分析
  • 2018-2030年美國自動化細胞處理/封閉式細胞治療處理系統市場規模及趨勢分析（依規模）
  • 預商業/研發規模
  • 商業規模

第7章 競爭格局

  • 參與企業
  • 策略規劃
  • 2024 年企業市場分析
  • 參與企業概況
    • Thermo Fisher Scientific Inc.
    • Lonza
    • MiltenyiBiotec
    • Danaher
    • Sartorius AG
    • Fresenus
    • MaxCyte, Inc.
    • ThermoGenesis Holdings, Inc.
    • Terumo Corporation
    • Cellares Inc.
Product Code: GVR-4-68040-486-1

U.S. Automated And Closed Cell Therapy Processing Systems Market Growth & Trends:

The U.S. automated and closed cell therapy processing systems market size is anticipated to reach USD 1.87 billion by 2030, growing at a CAGR of 19.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing emphasis on regenerative medicines and cell therapies, operational superiority of automated systems over manual processing, and extensively increasing technological advancements are some of the major factors driving the growth of the market.

The growing awareness about regenerative medicine is expected to drive the demand for cell therapies, eventually driving the need for automated and closed-cell therapy processing systems and fueling market growth. For instance, in September 2024, Arsenal Biosciences completed a USD 325 million Series C funding round, which was oversubscribed. This funding will help the company advance its CAR T-cell therapies for solid tumors. Existing investors supported the company, including the Parker Institute for Cancer Immunotherapy, SoftBank Vision Fund 2, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.

The COVID-19 pandemic underscored the critical need for scalable, resilient manufacturing in cell therapies, emphasizing automated systems' role in ensuring consistent, repeatable quality processes amid rising demand for therapeutics. Automation helps companies maintain production standards when faced with workforce constraints, making it essential for current and anticipated therapeutic needs. The increased adoption of automated systems highlighted the technology's role in establishing reliable, high-quality cell therapy manufacturing.

Despite these advancements, the pandemic also negatively affected the U.S. automated and closed-cell therapy processing systems market. Global supply chain disruptions caused delays in production and distribution, limiting the ability to maintain steady supply lines for essential equipment and materials. Resources were also redirected toward COVID-19 treatments, pausing certain cell therapy projects and slowing innovation. As a result, some development and manufacturing timelines for cell therapies were extended, impacting both research and commercialization efforts in the short term.

Moreover, many ongoing clinical trials coupled with the increasing support from government bodies to accelerate the R&D of cell therapy are major drivers of the U.S. market. For instance, in October 2024, New York launched the ambitious BioGenesis Park project on Long Island, supported by a USD 430 million investment. This facility aims to be a major hub for cell and gene therapy innovation, driven by a USD 150 million state investment and partnerships with local organizations. Such initiatives are expected to boost the adoption of automated systems for cell therapy manufacturing.

However, as the technology is relatively new, it requires a deep understanding of the process and a well-articulated strategy to achieve desired outcomes. Furthermore, providing enough data for the system to understand the process is necessary. After this step, one needs to understand process control for automation. This overall progression requires skilled manpower and high-end devices. There is a shortage of compatible hardware platforms that can help achieve automation in cell therapy processes. The need for extensive capital is expected to impede market growth to a certain extent.

U.S. Automated And Closed Cell Therapy Processing Systems Market Report Highlights:

  • Based on workflow, the separation segment dominated the market with the highest revenue share of 31.10% in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. The large share is attributed to the increasing demand for efficient cell isolation and purification techniques in therapeutic applications
  • Based on the type, the non-stem cell therapy segment dominated the market in 2024 with a share of 61.84%. This can be attributed to increasing product launches for non-stem cell therapy applications
  • Based on scale, the pre-commercial/R&D scale segment held the largest share of 74.96% in 2024. These systems are used primarily in early-stage research, process development, and clinical trials

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Workflow Segment
    • 1.2.2. Type Segment
    • 1.2.3. Scale Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing emphasis on regenerative medicines and cell therapies
      • 3.2.1.2. Operational superiority of automated systems over manual processing
      • 3.2.1.3. Extensively increasing technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Complications associated with cell processing systems
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Automated and Closed Cell Therapy Processing Systems Market: Workflow Business Analysis

  • 4.1. Workflow Segment Dashboard
  • 4.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Workflow Movement Analysis
  • 4.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
  • 4.4. Separation
    • 4.4.1. Separation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Expansion
    • 4.5.1. Expansion Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Apheresis
    • 4.6.1. Apheresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Fill-finish
    • 4.7.1. Fill-finish Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cryopreservation
    • 4.8.1. Cryopreservation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Automated and Closed Cell Therapy Processing Systems Market: Type Business Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Type, Movement Analysis
  • 5.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis by Type, 2018 to 2030 (USD Million)
  • 5.4. Stem Cell Therapy
    • 5.4.1. Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Non-stem Cell Therapy
    • 5.5.1. Non-stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Automated and Closed Cell Therapy Processing Systems Market: Scale Business Analysis

  • 6.1. Scale Segment Dashboard
  • 6.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Scale Movement Analysis
  • 6.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Scale, 2018 to 2030 (USD Million)
  • 6.4. Pre-commercial/ R&D Scale
    • 6.4.1. Pre-commercial/ R&D Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Commercial Scale
    • 6.5.1. Commercial Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2024
  • 7.4. Participant's Overview
    • 7.4.1. Thermo Fisher Scientific Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Lonza
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. MiltenyiBiotec
      • 7.4.3.1. Overview
      • 7.4.3.2. Product Benchmarking
      • 7.4.3.3. Strategic Initiatives
    • 7.4.4. Danaher
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Sartorius AG
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Fresenus
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. MaxCyte, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Product Benchmarking
      • 7.4.7.3. Strategic Initiatives
    • 7.4.8. ThermoGenesis Holdings, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Product Benchmarking
      • 7.4.8.3. Strategic Initiatives
    • 7.4.9. Terumo Corporation
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Cellares Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Product Benchmarking
      • 7.4.10.3. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Automated and Closed Cell Therapy Processing Systems market, by workflow, 2018 - 2030 (USD million)
  • Table 4 U.S. Automated and Closed Cell Therapy Processing Systems market, by type, 2018 - 2030 (USD million)
  • Table 5 U.S. Automated and Closed Cell Therapy Processing Systems market, by Scale, 2018 - 2030 (USD million)
  • Table 6 U.S. Automated and Closed Cell Therapy Processing Systems market, by region, 2018 - 2030 (USD million)
  • Table 7 Participant's overview
  • Table 8 Financial performance

List of Figures

  • Fig. 1 U.S. Automated and Closed Cell Therapy Processing Systems Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 U.S. Automated and Closed Cell Therapy Processing Systems Market Driver Analysis
  • Fig. 12 U.S. Automated and Closed Cell Therapy Processing Systems Market Restraint Analysis
  • Fig. 13 Porter's analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 U.S. Automated and Closed Cell Therapy Processing Systems market: Workflow outlook and key takeaways
  • Fig. 16 U.S. Automated and Closed Cell Therapy Processing Systems market: Workflow market share analysis, 2023 - 2030
  • Fig. 17 Separation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Expansion market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Apheresis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Fill-finish flasks market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Cryopreservation permeable membrane flasks market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Automated and Closed Cell Therapy Processing Systems market: Type outlook and key takeaways
  • Fig. 24 U.S. Automated and Closed Cell Therapy Processing Systems market: Type market share analysis, 2023 - 2030
  • Fig. 25 Stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Non-stem cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Automated and Closed Cell Therapy Processing Systems market: Scale outlook and key takeaways
  • Fig. 28 U.S. Automated and Closed Cell Therapy Processing Systems market: Scale market share analysis, 2024 - 2030
  • Fig. 29 Pre-commercial/ R&D scale market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Commerical scale market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Key company categorization
  • Fig. 32 Company market positioning
  • Fig. 33 Market participant categorization
  • Fig. 34 Strategy framework